In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient Therapeutics (ASX: PTX) CEO James McDonnell provides investors with a company update.

In this session Xsights Co-Founder and CEO Steve Wildisen provides investors with a company update.

In this session Xsights Co-Founder and CEO Steve Wildisen provides investors with a company update.

In this session Copper Bay Resources Chairman Joseph Webb provides investors with a company update.

In this session Merkle Tree Capital’s CEO Dean Serroni discussed how they managed to become Australia’s #1 performing fund in FY24 in the AFR’s annual fund survey.

In this session Wellnex Life Managing Director Zack Bozinvoski discussed their game-changing deal with $60bn health giant Haleon.

In this session Wellnex Life Managing Director Zack Bozinvoski discussed an update on the company’s recent progress, including its financial traction and UK IPO.

In this session Copper Bay Resources Chairman Joseph Webb provides investors with a company update.

In this session Felix Gold Executive Director Joseph Webb discussed Auger sampling results from the NE Fairbanks Project confirming significant soil anomalies, with peak gold values of 568 ppb Au.

In this session, Plutonic Managing Director Kris Butera and Non-Executive Chairman Hedley Widdup discussed drilling targets, including Perseverance, Loki North and Ridonkulous.

In this session Felix Gold Executive Director Joseph Webb discussed Auger sampling results from the NE Fairbanks Project confirming significant soil anomalies, with peak gold values of 568 ppb Au.